WP
AXSM icon

Woodline Partners’s Axsome Therapeutics AXSM Stock Holding History

Woodline Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.4M Buy
162,221
+11,357
+8% +$1.96M 0.1% 264
2025
Q4 		$27.6M Sell
150,864
-181,000
-55% -$25.3M 0.11% 250
2025
Q3 		$40.3M Buy
331,864
+733
+0.2% +$82.6K 0.19% 149
2025
Q2 		$34.6M Buy
331,131
+27,047
+9% +$2.86M 0.18% 155
2025
Q1 		$35.5M Sell
304,084
-104,357
-26% -$11.9M 0.23% 137
2024
Q4 		$34.6M Buy
408,441
+109,872
+37% +$10.1M 0.23% 135
2024
Q3 		$26.8M Sell
298,569
-19,442
-6% -$1.7M 0.23% 145
2024
Q2 		$25.6M Sell
318,011
-42,117
-12% -$3.12M 0.24% 131
2024
Q1 		$28.7M Sell
360,128
-202,035
-36% -$17M 0.26% 117
2023
Q4 		$44.7M Buy
562,163
+110,056
+24% +$7.36M 0.49% 61
2023
Q3 		$31.6M Buy
452,107
+12,182
+3% +$911K 0.37% 66
2023
Q2 		$31.6M Sell
439,925
-130,900
-23% -$9.66M 0.37% 71
2023
Q1 		$35.2M Buy
570,825
+347,173
+155% +$22.8M 0.48% 51
2022
Q4 		$17.3M Buy
+223,652
New +$13.4M 0.23% 132

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners's AXSM Position: Q1 2026 in Review

Woodline Partners increased its Axsome Therapeutics (AXSM) stake by 7.5% in Q1 2026, buying an estimated $1.96M and bringing the position to 162,221 shares worth $27.4M. The position accounts for 0.1% of the portfolio, ranked #264.

Woodline Partners first reported a position in AXSM in Q4 2022 and has held it in 14 quarters since. The position peaked at $44.7M in Q4 2023. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Woodline Partners held 162,221 shares of Axsome Therapeutics worth $27.4M as of Q1 2026.
  • Woodline Partners bought 11,357 Axsome Therapeutics shares in Q1 2026, an estimated $1.96M.
  • Axsome Therapeutics made up 0.1% of Woodline Partners's portfolio in Q1 2026, its #264 holding.
  • Woodline Partners first reported a position in Axsome Therapeutics in Q4 2022 and has held it in 14 quarters since.
  • Woodline Partners's Axsome Therapeutics position peaked at $44.7M in Q4 2023.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Woodline Partners's 13F filing for Q1 2026, filed 15 May 2026.